Clinical Trials · NCT01823835

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Name: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 1/Phase 2Gonadorelin

Phase: Phase 1/Phase 2
Recruitment status: Terminated
Sponsor: Genentech, Inc.
Enrollment: 152
Start date: Dec 2014
Locations: 14 sites, 4 countries
Primary endpoint: Phase Ia: Maximum Tolerated Dose of GDC-0810 When Used as a Single Agent

View Gonadorelin compound reference